(Total Views: 1329)
Posted On: 06/07/2022 5:07:25 PM
Post# of 155919
or better yet...
https://www.jemperlihcp.com/mechanism-of-action/
What about a joint venture with GSK in a combo trial with PD-1 Blockade Jemperli?
Jemperli with Leronli? Just thinking...
PD-1, PD-L1 & PD-L2 Blockade + CCR5 Blockade on mTNBC?
Jemperli has 13% anemia as worst side effect.
To avoid chemo, if anemia was the worst these mTNBC patients got, they'd take it in a heart beat.
In advanced Rectal Cancer, Jemperli:
and
from : https://www.onclive.com/view/dostarlimab-elic...tal-cancer
https://www.jemperlihcp.com/mechanism-of-action/
What about a joint venture with GSK in a combo trial with PD-1 Blockade Jemperli?
Jemperli with Leronli? Just thinking...
PD-1, PD-L1 & PD-L2 Blockade + CCR5 Blockade on mTNBC?
Jemperli has 13% anemia as worst side effect.
To avoid chemo, if anemia was the worst these mTNBC patients got, they'd take it in a heart beat.
In advanced Rectal Cancer, Jemperli:
Quote:
“No patients have required chemotherapy, radiation, or surgery [and] there has been no disease recurrence observed during the follow-up period,” Andrea Cercek, MD
and
Quote:
In conclusion we believe these data provide the framework for immunoablative therapies. It highlights the clinical impact of biomarker-driven therapy, in other words of moving precision medicine into early-stage disease.”
from : https://www.onclive.com/view/dostarlimab-elic...tal-cancer
(4)
(0)
